在动荡的市场环境中，市值15.5亿美元的Structure Therapeutics ADR (GPCR)股价已触及52周低点，跌至25.89美元。根据 InvestingPro ...

该研究首次发现并命名了一种肠道激素——Cholesin（肠抑脂素），并揭示了Cholesin调控机体 胆固醇 ...

在这充满显著波动的一年里，Structure Therapeutics的股票GPCR创下了新的52周低点，跌至26.21美元，与其52周高点62.74美元形成鲜明对比。 InvestingPro 数据显示，该公司保持着27.63的稳健流动比率，表明其短期流动性强劲。这一最新价格水平与过去一年的股票表现形成了鲜明对比， InvestingPro ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

G protein-coupled receptors (GPCRs), crucial for diverse physiological responses, have traditionally been investigated in ...

Exicure joins hands with GPCR Therapeutics for growth in biotech: Chicago Saturday, December 28, 2024, 14:00 Hrs [IST] Exicure, Inc., an early-stage biotechnology company, has ann ...

(Nasdaq: XCUR, "Exicure", "the Company"), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the ...

Structure Therapeutics, Inc. Sponsored ADR (GPCR) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay ...

Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of ...

Fintel reports that on January 8, 2025, Stifel initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $27.49 per share.

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...